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2nd Half Pregnancy  
Intrauterine Growth Restriction: Diagnostics 
Background 
1. Definition  
o Intrauterine growth restriction (IUGR)  
 Fetus w/ estimated wt <10th percentile for gestational age 
o Small for gestation age (SGA)  
 Infant w/ birth wt <10th percentile 
o Constitutionally small  
 Healthy infants on low-end of growth curve 
2. General info  
o 10% of all pregnancies will meet criteria for IUGR based on percentage cut-off  
 Many will be nml, constitutionally small 
 Must differentiate nml from pathologic 
 Lower cut-off may be more accurate in finding pathologic processes (5th 
or 3rd percentile) 
o IUGR diagnosis controversial  
 Guidelines for diagnosis and mgmt vary by country  
 This summary follows ACOG guidelines 
3. Normal fetal growth patterns  
o Cellular hyperplasia (1st 16 wks) 
o Hyperplasia and hypertrophy (16-32 wks) 
o Cellular hypertrophy (32-term) 
o Head circumference (HC) / abdominal circumference (AC) ratios:  
 Decr linearly through pregnancy 
4. Abnormal fetal growth patterns  
o Symmetric:  
 20-30% of IUGR  
 All fetal organs decr proportionally, impairment of early fetal cellular 
hyperplasia (genetic abnl) 
o Asymmetric:  
 70-80% of IUGR 
 Greater decr in AC (liver, SQ fat) compared w/HC, fetal adaptation to 
hostile environment (redistribution of blood flow to vital organs at 
expense of nonvital organs) 
5. Abbreviations  
o AC: abdominal circumference 
o AFV: amniotic fluid volume 
o AGA: appropriate for gestational age 
o EFW: estimated fetal weight 
o EGA: estimated gestational age 
o FH: fundal height 
o FL: femur length 
o GA: gestational age 
o HC: head circumference 
o SGA: small for gestational age 
o S/D ratio: systolic / diastolic ratio 
Pathophysiology 
1. Pathology  
o Variable, dependant on etiology 
o Uteroplacental insufficiency  
 Decr supply of nutrients/oxygen to developing fetus 
o See risk factors 
2. Incidence  
o By defn 10% of all pregnancies will meet criteria 
o Incidence of pathologic IUGR <10% 
3. Risk factors  
o Maternal medical conditions  
 HTN, preeclampsia 
 Chronic renal dz 
 Hypoxia  
 Cyanotic heart dz 
 Lung dz 
 High altitude 
 Diabetes 
 SLE/antiphospholipid syndrome 
 Collagen vascular dz 
 Hemoglobinopathies 
o Maternal behavioral conditions 
 Smoking 
 Alcohol use 
 Substance abuse, including  
 Methadone 
 Cocaine 
 Heroin 
 Poor wt gain, malnutrition 
 Hx of prior SGA infant 
 Maternal age extremes (<16 yo or >35) 
 Low socioeconomic status 
o Placental 
 Small placental size 
 Abruption 
 Previa 
 Infarcts 
 Confined placental mosaicism 
 Chorioangioma 
o Fetal  
 Genetic abnormalities  
 Aneuploidy 
 Trisomy 
 Ring chromosomes 
 Congenital malformations  
 Anencephaly 
 Multiple gestation 
 Infections  
 Rubella 
 CMV 
 Varicella 
 Toxoplasmosis 
 Syphilis 
 Teratogen exposure  
 Warfarin 
 Phenytoin 
 Methotrexate 
4. Morbidity /mortality  
o Sig incr risk for oligohydramnios and stillbirth  
 Depends on GA, etiology, deg of IUGR/SGA 
o Higher rates of cesarean delivery due to incr incidence of abnormal heart tones 
and oligohydramnios 
o Neonatal polycythemia, hyperbilirubinemia, hypoglycemia, hypothermia, apnea 
o Low APGARs 
Diagnostics 
1. History  
o Assess for presence of risk factors  
2. Physical exam  
o Screen all pregnancies with serial FH measurements  
 FH: upper edge pubic symphysis to top of fundus  
 Approximates GA after 20 wks gestation 
 Serial measurements starting at 20 wks gestation 
 Difference of 3 cm from EGA: abnormal  
 Esp at 32-34 wks GA 
 Accuracy varies widely  
 Improved if same provider examines every time  
3. Initial evaluation  
o Accurate GA is crucial 
o Screen for risk factors  
o Fetal anatomic survey  
 Identify major congenital anomalies 
o Fetal karyotyping  
 Structural abnl, early or severe IUGR, polyhydramnios 
 10-20% of structural abnormalities have abnl karyotype 
o Infectious dz evaluation  
 Maternal serum studies  
 Suspicion of infection 
 Check for evidence of seroconversion (CMV, rubella, VZV) 
 Amniotic fluid testing for viral DNA as indicated 
o Thrombophilic disorder  
 Especially if recurrent, early or severe 
 ATIII, protein C&S, Factor V Leiden, prothrombin gene mutation (PCR), 
APLAb, homocysteine  
4. Periodic evaluation  
o Optimal method and frequency not established  
 Test to determine benefit of preterm delivery 
 Start at point of viability 
o Serial EFW (U/S): every 2-4 wks 
o Biophysical Profile (BPP) 
 1-2/wk 
 Every day if >1 significant abnl 
 Severe IUGR (<3rd percentile), severe oligohydramnios, absent or 
reversed flow on Doppler, borderline BPP scores  
 Insufficient evidence to evaluate BPP as test of fetal well-being in 
high risk pregnancies 
o Amniotic fluid: part of BPP 
o Doppler velocimetry: 1/wk  
 Abnl umbilical vein or ductus venosus highest risk of imminent demise 
o Fetal blood sampling  
 Assess fetal acid base status to assist timing of delivery 
 9-14% procedure-related loss so repeat use limited due to high loss rate 
5. Diagnostic tests  
o U/S should be done for high-risk pregnancies or those with discordant fundal 
heights  
 EFW 
 Fetal biometrics 
 Anatomic survey 
 Amniotic fluid volume 
o Biophysical profile  
 Not indicated for initial Dx of IUGR 
o Doppler U/S  
 Not indicated for initial Dx of IUGR 
Therapeutics 
1. Acute Tx  
o Appropriately timed delivery  
 Only intervention that improves morbidity/mortality of IUGR infant  
2. Further mgmt (24 hrs)  
o Antenatal surveillance  
 Indicated once Dx of IUGR confirmed and fetus is viable  
 Goal to assess fetal growth rate, fetal well being, and amniotic fluid 
volumes to minimize complications 
 Methods of antenatal surveillance  
 Serial Doppler U/S for absence or reversal of flow in the umbilical 
cord  
 Serial BPPs, modified BPPs, or non-stress tests 1-2x per week 
 Serial U/S for growth rate (q2-4 wk) 
 Interventions  
 If antenatal surveillance reassuring, continue 
 If antenatal surveillance nonreassuring, consider prompt delivery 
 Term and late preterm infants should be delivered 
 Preterm infants <34 wks GA with IUGR are more complicated; 
require perinatal input as to their timing 
 Evaluation of fetal lung maturity may help in decision to deliver 
o Other studies  
 Karyotyping indicated in extreme IUGR or if anatomic abnormalities 
present 
Follow-Up 
1. Return to office  
o Timeframe for return visit  
 Weekly for antenatal testing  
2. Refer to specialist  
o Consider referral to high-risk OB once Dx confirmed  
3. Admit to hospital  
o For induction/delivery if antenatal testing nonreassuring  
Prognosis 
1. Prognosis depends on etiology  
o Guarded prognosis  
 Intrinsic fetal factors (aneuploidy, congenital malformations, infection) 
o Better prognosis  
 Inadequate substrates for fetus and decreased O2 (dependent upon eval, 
monitoring and timing of delivery) 
2. Recurrence risk  
o SGA risk in 2nd pregnancy 29% (vs 9% if 1st pregnancy AGA) 
o SGA risk in 3rd pregnancy after 2 SGA births 44% 
3. Long-term outcomes of infants  
o Normal catch-up of growth by age 2 in most cases 
o 2x incr risk of neurological sequalae 
o More prone to HTN and CVD as adults 
Prevention 
1. No evidence that the following treat IUGR  
o Nutrient/mineral supplementation  
o Volume expansion  
o Maternal oxygen therapy  
o Antihypertensive therapy  
o Heparin  
o ASA  
2. Avoid smoking during pregnancy  
Patient Education 
1. Handout from American Academy of Family Physicians  
o http://familydoctor.org/online/famdocen/home/women/pregnancy/fetal/313.html  
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